William S. M. Wold, Ph.D.
Education
Institution and Location	Degree	Year Conferred	Field of Study
Univ. of Manitoba, Winnipeg, Canada	B.Sc.	1965	Micro., Chem., Math
Univ. of Manitoba, Winnipeg, Canada	M.Sc.	1968	Microbiology
Univ. of Manitoba, Winnipeg, Canada	Ph.D.	1973	Microbiology
Inst. for Molecular Virology, St. Louis University	Post-Doc	1973-75	Molecular Virology

Research and/or Professional Experience
Dates	Employment/Institutions
1975-1976	Instructor, Institute of Molecular Virology, St. Louis University School of Medicine
1976-1979	Assistant Professor, Institute for Molecular Virology, St. Louis University School of Medicine
1979-1986	Associate Professor, Institute for Molecular Virology, St. Louis University School of Medicine
1992-Present	Professor and Chairman, Dept. of Molec. Microbiol. & Immunol., St. Louis Univ. School of Medicine
1999-2001	President and CEO, VirRx, LLC
2001-Present	President and CEO, VirRx, Inc.

Awards
University of Manitoba Predoctoral Fellowship (1968)	Canadian National Research Council Predoctoral Scholarship (1969-73)
Canadian Medical Research Council Postdoctoral Fellowship (1973-76)	National Institutes of Health Research Career Development Award (1980-85)
State-of-the-Art Speaker: "Virus-encoded Defense Molecules", American Society for Virology, Ithica, NY (1992)	Cancer Research Campaign Lecturer, The British Biochemical Society, 42nd Harden Conference, Wye College, Kent, UK (1994)
Keynote Speaker: "Viral Pathogenesis and Control", the 10th International Congress of Virology, Jerusalem, Israel (1966)	Nobel Symposium 106, "Intracellular and Persisten Infections", Stockholm, Sweden (1998)
Keynote Speaker: "Cancer-specific Replication-Competent Adenovirus Vectors", CapCURE Prostate Cancer Research Retreat, Lake Tahoe, NV (2000)	Distinguished Lecturer Series, Miami University, Oxford, OH (2001)
Fellow, The Academy of Sciences of St. Louis (2002-present)
Advisory Groups
Panel Member, Developmental Biology, National Science Foundation (1986-88)	Associate Editor, Virology (1989-Present)
National Institutes of Health Reviewers Reserve (1990-Present)	British Columbia Health Service (1992-Present)
Associate Editor, Journal Virology (1997-Present)	Associate Editor, Viral Immunology (2000-Present)

Invited Plenary Section Symposium Lecturers

"Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein", CaPCURE-sponsored First Annual meeting, Gene Therapy Summit for Prostate Cancer, Atlanta, GA, 2000.     "Cancer-Specific Replication-Competent Adenovirus Vectors", CapCURE Prostate Cancer Research Retreat, Lake Tahoe, NV, 2000.     Ethical Challenges for Graduate Education: Entrepreneurial Faculty, "Experiences of Faculty", 57th Annual Meeting, Midwestern Association of Graduate Schools, St. Louis, MO, 2001.     "Adenovirus Oncolytic Vectors for Cancer Gene Therapy", CaPCURE-sponsored Second Annual meeting, Gene Therapy Summit for Prostate Cancer, Baltimore, MD, 2001.     "Adenovirus Cancer Gene Therapy: Tumor-Specific Replication-Competent Vectors", at 2nd International Conference, M.D. Anderson Cancer Center and European School of Haematology; Mechanisms of Cell Death & Disease: Advances in Therapeutic Intervention, North Falmouth, MA, 2001.     "Gene Therapy and Radiation Therapy for the Treatment of Prostate Cancer", RTOG meeting, Philadelphia, PA, 2001     "Viral Vectors for Cancer Gene Therapy", American Association for Cancer Research meeting on Molecular Imaging in Cancer, Orlando, FL, January 2002.     Gene Therapy Advisory Committee 2002 Open Meeting, Gene Therapy in Cancer, Royal College of Physicians, London, UK, March 4, 2002.     "Viral Vectors for Cancer Gene Therapy", American Society of Gene Therapy, 5th annual meeting, Boston, MA, June 9, 2002.     "Adenovirus Cancer Gene Therapy and Vaccine Vectors: Using Biotechnology for Homeland Defense", BIO2002, Toronto, Canada, June 12, 2002.     "Starting a Biotech Company in the University Environment and Adopting the Technology Platform to Funding Opportunities in Biodefense", BioMed Expo 2002, Ann Arbor, MI, October 24, 2002.     "Adenovirus Oncolytic Vectors that Overexpress ADP", Oncolytic Viruses as Cancer Therapeutics, American Society for Microbiology, Banff, Canada, March 28, 2003.     "Adenovirus Oncolytic Vectors that Overexpress the Adenovirus Death Protein (ADP)", American Society for Gene Therapy, 6th Annual Meeting, Washington, D.C., June, 2003. Workshop presentation.     "Oncolytic Adenoviral Vectors Overexpressing ADP", Twelfth International Conference on Gene Therapy of Cancer, San Diego, CA, December 12, 2003.     "Oncolytic Adenoviral Vectors Overexpressing ADP", Gordon Research Conference on Viral Vectors for Gene Therapy, Santa Barbara, CA, February, 12, 2004.     "Adenovirus Vectors", American Society of Gene Therapy, 7th Annual Meeting, Minneapolis, MN, June 2, 2004.     "Tumor Specific Oncolytic Adenovirus Vector VRX-011 Which Overproduces ADP and Has the E4 Promoter Replaced by the hTERT Promoter", American Society of Gene Therapy, 7th Annual Meeting, Minneapolis, MN, June 6, 2004.     "Adenovirus Replication-Competent "Vector" for Treatment of Cancer", American Society of Clinical Oncologists, New Orleans, LA, June 6, 2004.     "Oncolytic Adenovirus Vectors that Overexpress ADP for Increased Efficacy: Evaluation in a Permissive, Immunocompetent, Syrian Hamster Model", American Society of Gene Therapy, 8th Annual Meeting, St. Louis, MO, June 2, 2005.

Selected Peer-Reviewed Publications Total Publications: 168

Gooding, L.R., Ranheim, T.S., Tollefson, A.E., Aquino, L., Duerksen-Hughes, P., Horton, T.M., and Wold, W.S.M. (1991) The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J. Virol. 65: 4114-4123.     Tollefson, A.E., Scaria, A., Saha, S.K., and Wold, W.S.M. (1992) The 11,600-Mw protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J. Virol. 66:3633-3642.     Scaria, A., Tollefson, A.E., Saha, S.K., and Wold, W.S.M. (1992) The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane. Virology 191:743-753.     Krajcsi, P., Tollefson, A.E., Anderson, C.W., Stewart, A.R., Carlin, C.R., and Wold, W.S.M. (1992) The E3-10.4K protein of adenovirus is an integral membrane protein that is partially cleaved between Ala22 and Ala23 and has a Ccyt orientation. Virology 187:131-144.     Krajcsi, P., and Wold, W.S.M. (1992) The adenovirus E3-14.5K protein which is required for prevention of TNF cytolysis and for down-regulation of the EGF receptor contains phosphoserine. Virology 187:492-498.     Krajcsi, P., Tollefson, A.E., Anderson, C.W., and Wold, W.S.M. (1992) The adenovirus E3 14.5-kilodalton protein, which is required for down-regulation of the epidermal growth factor receptor and prevention of tumor necrosis factor cytolysis, is an integral membrane protein oriented with its C terminus in the cytoplasm. J. Virol. 66:1665-1673.     Krajcsi, P., Tollefson, A.E., and Wold, W.S.M. (1992) The E3-14.5K integral membrane protein of adenovirus that is required for down-regulation of the EGF receptor and for prevention of TNF cytolysis is O-glycosylated but not N-glycosylated. Virology 188:570-579.     White, E., Sabbatini, P., Debbas, M., Wold, W.S.M., Kusher, D. I., and Gooding, L. R. (1992) The 19-KDa adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by TNF-a. Mol. Cell. Biol. 12:2570-2580.     Hoffman, P., Yaffe, M.B., Hoffman, B.L., Yei, S., Wold, W.S.M., and Carlin, C. (1992) Characterization of the adenovirus 10.4K protein that down-regulates the epidermal growth factor receptor: Evidence for intermolecular disulfide-bonding and plasma membrane localization. J. Biol. Chem. 267:13480-13487.     Ranheim, T.S., Shisler, J., Horton, T.M., Wold, L.J., Gooding, L.R., and Wold, W.S.M. (1993) Characterization of mutants within the gene for the Ad5 E3-14.7K protein which prevents cytolysis by TNF. J. Virol. 67:2159-2167.     Hermiston, T.W., Tripp, R.A., Sparer, T., Gooding, L.R., and Wold, W.S.M. (1993) Deletion mutant analysis of the Ad2 E3-gp19K protein: Identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67:5289-5298.     Scaria, A., and Wold, W.S.M. (1994) Fine-mapping of sequences that suppress splicing in the E3 complex transcription unit of adenovirus. Virology 205:406-416.     Voelkel-Johnson, C., Entingh, A.J., Wold, W.S.M., Gooding, L.R., and Laster, S.M. (1995) Activation of intracellular proteases is an early event in TNF-induced apoptosis. J. Immunol. 154:1707-1716.     Stewart, A.R., Tollefson, A.E., Krajcsi, P., and Wold, W.S.M. (1995) The adenovirus E3 10.4K and 14.5K proteins, which function to prevent TNF cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane. J. Virol. 69:172-181.     Hawkins, L.K., and Wold, W.S.M. (1995) A 20,500-dalton protein is coded by region E3 of subgroup B but not subgroup C human adenoviruses. Virology 208:226-233.     Hawkins, L.K., Wilson-Rawls, J., and Wold, W.S.M. (1995) Region E3 of subgroup B human adenoviruses encodes a 16,000 MW membrane protein that may be a distant analog of the E3-6.7K protein of subgroup C adenoviruses. J. Virol. 69:4292-4298.     Hawkins, L.K., and Wold, W.S.M. (1995) The E3-20.5K membrane protein of subgroup B human adenoviruses is modified by O-linked and complex N-linked oligosaccharides. Virology 210: 335-344.     Shisler, J., Duerksen-Hughes, P., Hermiston, T.W., Wold, W.S.M., and Gooding, L.R. (1996) Induction of susceptibility to TNF by adenovirus E1A is dependent upon binding to p300 or p105-Rb and induction of DNA synthesis. J. Virol. 70:68-77.     Sparer, T., Tripp, R.A., Dillehay, D.L., Hermiston, T.W., Wold, W.S.M., and Gooding, L.R. (1996) The role of adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70:2431-2439.     Tollefson, A.E., Scaria, A., Hermiston, T.W., Ryerse, J.S., Wold, L.J., and Wold, W.S.M. (1996) The Adenovirus Death Protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70:2296-2306.     Krajcsi, P., Dimitrov, T., Hermiston, T.W., Tollefson, A.E., Ranheim, T.S., Vande Pol, S.B., and Wold, W.S.M. (1996) The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which function independently to inhibit TNF-induced apoptosis, also function independently to inhibit TNF-induced release of arachidonic acid. J. Virol. 70:4904-4913.     Tollefson, A.E., Ryerse, J.S., Scaria, A., Hermiston, T.W., and Wold, W.S.M. (1996) The E3-11.6KDa Adenovirus Death Protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220:152-162.     Dimitrov, T., Krajcsi, P., Hermiston, T.W., Tollefson, A.E., Hannink, M., and Wold, W.S.M. (1997) Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Virol. 71:2830-2837.     Tollefson, A.E., Hermiston, T.W., Lichtenstein, D.L., Colle, C.F., Tripp, R.A., Dimitrov, T., Toth, K., Wells, C.E., Doherty, P.C., and Wold, W.S.M. (1998) Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392:726-730.     Harrod, K.S., Hermiston, T.W., Trapnell, B.C., Wold, W.S.M., and Whitsett, J.A. (1998) Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression. Human Gene Ther. 9:1885-1898.     Li, Y., and Wold, W.S.M. (2000) Identification and characterization of a 30K protein (Ad4 E3-30K) encoded by the E3 region of human adenovirus type 4. Virology 273:128-138.     Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A.E., and Wold, W.S.M. (2000) Tumor specific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein. J. Virol. 74:6147-6155.     Johnstone, R.W., Gerber, M., Landewe, T., Tollefson, A.E., Wold, W.S.M., and Shilatifard, A. (2001) Functional analysis of the leukemia protein ELL: Evidence for a role in the regulation of cell growth and survival. Mol. Cell. Biol. 21:1672-1681.     Doronin, K., Kuppuswamy, K., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V., and Wold, W.S.M. (2001) Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75:3314-3324.     Tollefson, A.E., Toth, K., Doronin, K., Kuppuswamy, M., Dorinova, D.A., Lichtenstein, D.L., Hermiston, T.W., Smith, C.A., and Wold, W.S.M. (2001) Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J. Virol. 75:8875-8887.     Toth, K., and Wold, W.S.M. (2002) HEK? No! Mol. Ther. 5:654.     Habib, N.A., Mitry, R., Seth, P., Kuppuswamy, M., Doronin, K., Toth, K., Krajcsi, P., Tollefson, A.E., and Wold, W.S.M. (2002) Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 9:651-654.     Toth, K., Kuppuswamy, M., Doronin, K., Doronin, O.A., Lichtenstein, D.L., Tollefson, A.E., and Wold, W.S.M. (2002) Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region. Virology 301:99-108.     Kladney, R.D., Tollefson, A.E., Wold, W.S.M., and Fimmel, C. J. (2002) Upregulation of the Golgi protein GP73 by adenovirus infection requires the adenoviral CtBP interaction domain. Virology 301:236-246.     Lichtenstein, D.L., Krajcsi, P., Esteban, D.J., Tollefson, A.E., and Wold, W.S.M. (2002) Adenovirus RIDß subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis. J. Virol. 76:11329-11342.     Doronin, K., Toth, K., Kuppuswamy, M., Krajcsi, P., Tollefson, A.E., and Wold, W. S. M. (2003) Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305:378-387.     Toth, K., Tarakanova, V., Doronin, K., Ward, P., Kuppuswamy, M., Locke, J. L., Dawson, J.E., Kim, H. J., and Wold, W.S.M. (2003) Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Therapy 10:193-200.     Toth, K., Doronin, K., Tollefson, A.E., and Wold, W.S.M. (2003) A multitasking oncolytic adenovirus vector. Molec. Ther. 7:435-437.     Ying, B., and Wold, W.S.M. (2003) Adenovirus ADP protein (E3-11.6K), which is required for efficient cell lysis and virus release, interacts with human MAD2B. Virology 313:224-234.     Tollefson, A.E., Scaria, A., Ying, B., and Wold, W.S.M. (2003) Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells. J. Virol. 77:7764-7778.     Tarakonova, V., and Wold, W.S.M. (2003) Transforming Growth Factor Beta 1 receptor II is downregulated by E1A in adenovirus-infected cells. J. Virol. 77:9324-9336.     Zanardi, T.A., Yei, S., Lichtenstein, D.L., Tollofson, A.E., and Wold, W.S.M. (2003) Distinct domains in the adenovirus E3 RID alpha protein are required for deregulation of Fas and the epidermal growth factor receptor. J. Virol. 77:11685-11696.     Lichtenstein, D.L., Toth, K., Doronin, K., Tollefson, A.E., and Wold, W.S.M. (2003) Functions and mechanisms of action of the adenovirus E3 proteins. International Reviews of Immunology, 23:75-111.     Toth, K., Djeha, H., Ying, B., Tollefson, A.E., Kuppuswamy, M., Doronin, K., Krajcsi, P., Lipinski, K., Wrighton, C.J., and Wold, W.S.M. (2004) An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt-signaling. Cancer Research 64, 3638-3644.     Lichtenstein, D.L., Doronin, K., Toth, K., Kuppuswamy, M., Wold, W.S.M., and Tollefson, A.E. (2004) Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL Receptor 2. Journal of Virology 78:12297-12307.     Lichtenstein, D.L. and Wold, W.S.M. (2004) Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Therapy 11:819-829.     Toth, K., Doronin, K., Kuppuswamy, M., Ward, P., Tollefson, A.E., and Wold, W.S.M. (2005) Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice. Virus Research 108:149-159.     Toth, K., Spencer, J.F., Tollefson, A.E., Kuppuswamy, M., Doronin, K., Lichtenstein, D.L., La Regina, M.C., Prince, G.A., and Wold, W.S.M. (2005) Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Human Gene Therapy 16:139-146.     Kuppuswamy, M., Spencer, J.F., Doronin, K., Tollefson, A.E., Wold, W.S.M., and Toth, K. (2005) Oncolytic adenovirus vector that overproduces the cytolytic ADP protein and replicates selectively in tumor cells due to regulation of E4 gene expression by the hTERT promoter. Gene Therapy 12:1608-1617.     Kanj, S.S., Dandashi, N., El-Hed, A., Harik, H., Maalouf, M., Kozhaya, L., Mousallem, T., Tollefson, A.E., Wold, William, W.S.M., Chalfant, C.E., and Dbaibo, G.S. (2006) Ceramide regulates SR protein phosphorylation duringadenoviral infection. Virology 345:280-289.     Tollefson, A.E., and Wold W.S.M., Editors, (2006) Adenovirus Methods and Protocols, 2nd edition, Humana Press, in press.     Thomas, M.A., Spencer, J.F., and Wold, William S.M. (2006) The use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. In “Adenovirus Methods and Protocols, 2nd Edition” (eds. W.S.M. Wold and A.E. Tollefson), The Humana Press, Inc., Totowa, New Jersey, (Methods in Molecular Biology), in press.     Tollefson, A.E. and Wold, W.S.M. (2006) Preparation and titration of CsCl-banded adenovirus stock. In “Adenovirus Methods and Protocols, 2nd Edition” (eds. W.S.M. Wold and A.E. Tollefson), The Humana Press, Inc., Totowa, New Jersey, (Methods in Molecular Biology), in press.     Toth, K., Spencer, J.F., and Wold, W.S.M. (2006) Immunocompetent, semi-permissive cotton rat tumor model for the evaluation of oncolytic adenoviruses. In “Adenovirus Methods and Protocols, 2nd Edition” (eds. W.S.M. Wold and A.E. Tollefson), The Humana Press, Inc., Totowa, New Jersey, (Methods in Molecular Biology), in press.     Thomas, M.A., Lichtenstein D.L., and Wold, W.S.M. (2006) A real-time PCR method to rapidly assay adenovirus stocks. In “Adenovirus Methods and Protocols, 2nd Edition” (eds. W.S.M. Wold and A.E. Tollefson), The Humana Press, Inc., Totowa, New Jersey, (Methods in Molecular Biology), in press.     Thomas, M.A., Spencer, J.F., La Regina, M.C., Tollefson, A.E., Toth, K., and Wold, W.S.M.. (2006) The Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors, Cancer Research 66:1-7.